Savara Class Action Over MOLBREEVI BLA
Analysis based on 8 articles · First reported Oct 06, 2025 · Last updated Oct 27, 2025
The class action lawsuit against Savara, following the United States — Food and Drug Administration's refusal to file its BLA, has led to a significant drop in Savara's stock price. This event highlights regulatory risks in the biotechnology sector and could lead to increased scrutiny of similar companies' disclosures.
A class action lawsuit has been filed against Savara by Bragar Eagel & Squire on behalf of investors who purchased Savara securities between March 7, 2024, and May 23, 2025. The lawsuit alleges that Savara failed to disclose critical information regarding its MOLBREEVI Biologics License Application (BLA), specifically that it lacked sufficient chemistry, manufacturing, and controls (CMC) data. This made it unlikely for the United States — Food and Drug Administration to approve the BLA in its current form, delaying regulatory approval and increasing the need for Savara to raise additional capital. On May 27, 2025, Savara announced that the United States — Food and Drug Administration issued a refusal to file letter for the MOLBREEVI BLA, causing Savara's stock price to fall by 31.69%.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard